UNASYN
Combination product
Pronunciation: am-pi-SIL-in and sul-BAK-tam
Combination of Ampicillin and Sulbactam.
Each component keeps its own pharmacology page; the combination itself adds no new mechanism.
Components (2)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Susceptible skin/skin-structure, intra-abdominal, and gynecologic infections | Adults & peds ≥40 kg | 1.5 g–3 g (ampicillin/sulbactam) IV q6h | Sulbactam ≤4 g/day | |
| Susceptible skin/skin-structure, intra-abdominal, and gynecologic infections | Peds ≥1 yr (<40 kg) | 300 mg/kg/day IV divided q6h | Sulbactam ≤4 g/day |
Renal Reduce dosing frequency by CrCl: ≥30 mL/min q6–8h; 15–29 q12h; 5–14 q24h.
Hepatic Undefined
Instructions
- Dilute in 50–100 mL compatible diluent; IV infusion over 15–30 min
- IV therapy should not routinely exceed 14 days
Available strengths
- inj 1.5, 3 g
Contraindications
- Serious hypersensitivity (e.g., anaphylaxis, Stevens-Johnson syndrome) to ampicillin, sulbactam, or other beta-lactams (penicillins/cephalosporins)
- Prior cholestatic jaundice/hepatic dysfunction associated with ampicillin/sulbactam
Cautions
- Serious hypersensitivity/anaphylaxis
- Hepatic dysfunction
- Clostridioides difficile-associated diarrhea
- Skin reactions
Adverse reactions
- Injection-site pain, thrombophlebitis/phlebitis
- Diarrhea
- Rash
- Nausea, vomiting
Pregnancy Animal studies show no fetal harm; no adequate human studies — use only if clearly needed.
Lactation Undefined
Cost
UNASYN
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 1.5 g | inj | per unit | not offered | |
| 3 g | inj | per unit | not offered |
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. UNASYN is administered under clinical supervision and dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.
Part D rank #363.